Elicio raises $33m to advance lymph node-targeted immuno-therapies

Filed under: Pharma Industry News | Tags: , , , , , , , ,

US immuno-oncology company Elicio Therapeutics has raised $33 million through a Series B financing round to advance ELI-002, an Amphiphile mKRAS vaccine (AMP KRAS), and other lymph node targeted immuno-therapies.

Elicio Therapeutics said that it has established an international investor base which includes Clal Biotechnology Industries, Efung Capital, and Livzon Pharmaceutical Group.

According to the US immuno-oncology company, ELI-002 targets all the seven KRAS mutations that are behind 99% of all mKRAS-driven cancers, which are estimated to amount to 25% of all human solid tumors.

The AMP KRAS vaccine has gone through preclinical validation, IND-enabling GLP toxicology studies, GMP manufacturing, and also a pre-IND meeting with the FDA.

Elicio raises $33m to advance ELI-002 vaccine and other lymph node-targeted immuno-therapies

Elicio raises $33m to advance ELI-002 vaccine and other lymph node-targeted immuno-therapies

Elicio Therapeutics revealed plans to start an initial patient study in pancreatic cancer patients in H1 2020.  The early-stage trials will be multi-site, randomized, controlled studies with initial ELI-002 pancreatic cancer patient data expected to be released in H2 2020.

Robert Connelly – CEO of Elicio Therapeutics said: “We believe ELI-002 can become a universal mKRAS vaccine with the potential to treat and prevent disease recurrence for hundreds of thousands of patients with mKRAS-driven cancers, including pancreatic, colorectal and lung cancer.

“This new funding is a strong endorsement of this program, the Amphiphile platform, and our progress.”

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *